A study suggesting that nirmatrelvir/ritonavir and molnupiravir don’t prevent severe COVID-19 outcomes or long COVID is also being called into question.
Evidence growing for COVID antivirals to cut poor outcomes, long COVID, experts say
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- COVID 2024-25 vaccines 33% protective against emergency room or urgent care visits, data reveal
- Paxlovid may better cut risk of severe COVID outcomes in asthma patients than molnupiravir
- US flu season shows signs of peak
- Hospitalized COVID patients at higher risk for organ-related death, readmission for 2.5 years, data suggest